Angiogenic Switch Antibody Sampler Kit #42790

The development of new blood vessels (angiogenesis) is essential for tumor growth. A tumor cannot exceed a few millimeters in size without an adequate blood supply, necessitating the activation of the "angiogenic switch"—a pathological transition from a dormant state to aggressive vascular proliferation. This switch is driven by the dynamic and coordinated activation of several major signaling hubs in response to the low oxygen environment characteristic of a growing tumor (1,2).

The initial signal is mediated by the hypoxia-inducible factor (HIF) pathway, which senses and responds to low oxygen. HIF-1alpha is the master regulator of this pathway: under hypoxic conditions, HIF-1alpha protein is stabilized (avoiding degradation) and translocates to the nucleus, where it drives the transcription of over a hundred genes, most importantly vascular endothelial growth factor-A (VEGF-A). VEGF-A is the key secreted growth factor produced by tumor cells and other stromal cells in response to HIF-1alpha activity, and it acts as the primary paracrine signal to force new vessel growth. VEGF-A binds to VEGF receptor 2 (VEGFR2), the main receptor on endothelial cells that mediates angiogenesis. Once bound to its ligand, VEGFR2 undergoes a conformational change, dimerizes, and becomes hyper-phosphorylated, thereby activating downstream pro-survival signaling pathways. VEGF-A/VEGFR2 signaling culminates in gene expression changes that promote endothelial cell proliferation (sprouting) and migration. This activity in the endothelium, along with increased vascular permeability, directly contributes to tumor vascularization (1-6). Within the hypoxic tumor microenvironment (TME), multiple inflammatory pathways are at play: signal transducer and activator of transcription 3 (STAT3) is an oncogenic signaling molecule that is often constitutively active in tumors, and it promotes endothelial cell (EC) survival and proliferation, creating a positive feedback loop that accelerates tumor progression. Various inflammatory cues in the TME activate NFkappaB (p65/RelA) signaling. It promotes the transcription of pro-angiogenic factors, notably VEGF-A, and facilitates the immune cell recruitment (7,8).

For a new vessel to sprout, endothelial cells must degrade the surrounding extracellular matrix (ECM). Matrix metalloproteinases (MMPs) are secreted proteolytic enzymes that perform this function. MMP-9 is produced by both tumor cells and tumor-associated macrophages (TAMs). Upregulation of MMP-9 is essential for breaking down the basement membrane and ECM, which permits endothelial cells to invade the surrounding tissue and establish a new vascular network (1,2,9).